Comparative Analysis of Bioactivity of the Russian-Made Antitumor Substances of the Nitrosourea Group

• Published in: Bulletin of experimental biology and medicine Vol. 166; no. 4; pp. 456 - 460
• Main Authors: Bunyatyan, N. D., Oborotova, N. A., Nikolaeva, L. L., Saprykina, N. S., Borisova, L. M., Kiseleva, M. P., Prokof’ev, A. B.
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.02.2019; Springer; Springer Nature B.V
• Subjects: Analysis; Animal models; Animals; Antineoplastic Agents - therapeutic use; Antitumor activity; Biological activity; Biomedical and Life Sciences; Biomedicine; Cancer; Cancer research; Carcinoma; Cell Biology; Cervical cancer; Cervix; Comparative analysis; Comparative literature; Female; House mouse; Internal Medicine; Laboratory Medicine; Leukemia; Leukemia L1210 - drug therapy; Leukemia P388 - drug therapy; Life span; Lung cancer; Lung carcinoma; Lymphatic leukemia; Lymphocytic leukemia; Mice; Neoplasms, Experimental - drug therapy; Nitrosourea Compounds - therapeutic use; Pathology; Russia; Solid tumors; Treatment Outcome; Tumors; Uterine Cervical Neoplasms - drug therapy; Russia; antitumor activity; nitrosourea-based substances; tumor
• ISSN: 0007-4888; 1573-8221; 1573-8221
• DOI: 10.1007/s10517-019-04371-w

We performed an in vivo comparative study of activity of three substances of the nitrosourea group produced in Russia. All substances demonstrated high antitumor activity against various solid and leukemic tumors. Aranosa significantly enhanced life duration in mice with leukemia (by 65-194%) and inhibited the growth of solid tumors (by 49-99.6%). Lisomustine and ormustine showed higher activity than aranose. Single administration of lisomustine increased life span of mice (by 22-114%) and resulted in cure of all animals in four models: lymphoblastic leukemia L-1210, lymphocytic leukemia P-388, Lewis lung carcinoma, and cervical cancer RShM-5. After ormustine treatment, full recovery was observed only in groups with lymphocytic leukemia P-388 and cervical cancer RShM-5. These findings attest to higher activity of lisomustine in the studied models.